Immunodiagnostic Systems Holdings Equity 2024

Immunodiagnostic Systems Holdings Aktienanalyse

What does Immunodiagnostic Systems Holdings do?

IDS, Immunodiagnostic Systems Holdings PLC, is an English-American diagnostic company that specializes in the development, manufacture, and marketing of diagnostic tests for various applications. The company was founded in 1977 in Boldon, England and is headquartered in Tyne and Wear. IDS started with a focus on researching enzyme immunoassays (EIA) and has expanded its offerings to include radioimmunoassays and chemiluminescent tests. IDS operates in sectors such as endocrinology, clinical chemistry, hematology, and oncology, and is known as a leading provider of diagnostic test kits in many countries. The company offers over 400 tests, including reagents, calibrators, controls, and devices for more than 200 different parameters. IDS sells its products through an international network of branches, distributors, and authorized dealers in Asia, Europe, North America, South America, and the Middle East. The company has also established subsidiaries in the US and China to expand its offerings and drive growth in these regions. IDS's business model is focused on meeting customer needs for reliable, accurate, and fast diagnostic solutions. The company adheres to the highest quality standards and is committed to the continuous development and improvement of its products to enhance patient care and laboratory work worldwide. IDS has made a name for itself in the diagnostic industry in recent years and is a pioneer in developing tests for emerging applications such as autoimmune diseases and food intolerances. The company invests heavily in research and development and collaborates closely with academic partners and research institutions to identify and develop innovative diagnostic solutions. In summary, IDS is a leading diagnostic company operating in various applications and offering a wide range of diagnostic test solutions. The company has experienced strong growth in recent years and is committed to expanding its product range and offerings to meet the needs of patients and laboratories worldwide. Immunodiagnostic Systems Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Immunodiagnostic Systems Holdings's Equity

Immunodiagnostic Systems Holdings's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immunodiagnostic Systems Holdings's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Immunodiagnostic Systems Holdings's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Immunodiagnostic Systems Holdings's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Immunodiagnostic Systems Holdings’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Immunodiagnostic Systems Holdings stock

What is the equity of Immunodiagnostic Systems Holdings this year?

Immunodiagnostic Systems Holdings has equity of 0 GBP this year.

What was the equity of Immunodiagnostic Systems Holdings compared to the previous year?

The equity of Immunodiagnostic Systems Holdings has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Immunodiagnostic Systems Holdings?

A high equity is advantageous for investors of Immunodiagnostic Systems Holdings as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Immunodiagnostic Systems Holdings?

A low equity can be a risk for investors of Immunodiagnostic Systems Holdings, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Immunodiagnostic Systems Holdings affect the company?

An increase in equity of Immunodiagnostic Systems Holdings can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Immunodiagnostic Systems Holdings affect the company?

A reduction in equity of Immunodiagnostic Systems Holdings can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Immunodiagnostic Systems Holdings?

Some factors that can affect the equity of Immunodiagnostic Systems Holdings include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Immunodiagnostic Systems Holdings so important for investors?

The equity of Immunodiagnostic Systems Holdings is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Immunodiagnostic Systems Holdings take to change the equity?

To change equity, Immunodiagnostic Systems Holdings can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Immunodiagnostic Systems Holdings pay?

Over the past 12 months, Immunodiagnostic Systems Holdings paid a dividend of 0.02 GBP . This corresponds to a dividend yield of about 50.26 %. For the coming 12 months, Immunodiagnostic Systems Holdings is expected to pay a dividend of 0.02 GBP.

What is the dividend yield of Immunodiagnostic Systems Holdings?

The current dividend yield of Immunodiagnostic Systems Holdings is 50.26 %.

When does Immunodiagnostic Systems Holdings pay dividends?

Immunodiagnostic Systems Holdings pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Immunodiagnostic Systems Holdings?

Immunodiagnostic Systems Holdings paid dividends every year for the past 15 years.

What is the dividend of Immunodiagnostic Systems Holdings?

For the upcoming 12 months, dividends amounting to 0.02 GBP are expected. This corresponds to a dividend yield of 50.26 %.

In which sector is Immunodiagnostic Systems Holdings located?

Immunodiagnostic Systems Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunodiagnostic Systems Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunodiagnostic Systems Holdings from 8/14/2020 amounting to 0.019 GBP, you needed to have the stock in your portfolio before the ex-date on 7/16/2020.

When did Immunodiagnostic Systems Holdings pay the last dividend?

The last dividend was paid out on 8/14/2020.

What was the dividend of Immunodiagnostic Systems Holdings in the year 2023?

In the year 2023, Immunodiagnostic Systems Holdings distributed 0.007 GBP as dividends.

In which currency does Immunodiagnostic Systems Holdings pay out the dividend?

The dividends of Immunodiagnostic Systems Holdings are distributed in GBP.